International Journal of Medical Sciences

Impact factor
2.399

20 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2009; 6(6):312-321. doi:10.7150/ijms.6.312

Research Paper

Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial

David C. Crowley1, Francis C. Lau2, Prachi Sharma1, Malkanthi Evans1, Najla Guthrie1, Manashi Bagchi2, Debasis Bagchi2,3, Dipak K. Dey4, Siba P. Raychaudhuri 5,6,✉

1. KGK Synergize Incorporated, London, ON, Canada
2. Department of Research and Development, InterHealth Research Center, Benicia, CA, USA
3. Department of Pharmacology and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, TX, USA
4. Department of Statistics, University of Connecticut, Storrs, CT, USA
5. Department of Medicine, Division of Rheumatology, Allergy and Immunology, School of Medicine, University of California Davis, Davis, CA, USA
6. VA Medical Center Sacramento, Hospital Way, Mather, CA, USA

Abstract

Previous studies have shown that undenatured type II collagen (UC-II) is effective in the treatment of rheumatoid arthritis, and preliminary human and animal trials have shown it to be effective in treating osteoarthritis (OA). The present clinical trial evaluated the safety and efficacy of UC-II as compared to a combination of glucosamine and chondroitin (G+C) in the treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious resulting in a significant reduction in all assessments from the baseline at 90 days; whereas, this effect was not observed in G+C treatment group. Specifically, although both treatments reduced the Western Ontario McMaster Osteoarthritis Index (WOMAC) score, treatment with UC-II reduced the WOMAC score by 33% as compared to 14% in G+C treated group after 90 days. Similar results were obtained for visual analog scale (VAS) scores. Although both the treatments reduced the VAS score, UC-II treatment decreased VAS score by 40% after 90 days as compared to 15.4% in G+C treated group. The Lequesne's functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II reduced Lequesne's functional index score by 20% as compared to 6% in G+C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed significant enhancement in daily activities suggesting an improvement in their quality of life.

Keywords: undenatured type II collagen, osteoarthritis, glucosamine, chondroitin, WOMAC, visual analog scale, Lequesne's Functional Index

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, Bagchi D, Dey DK, Raychaudhuri SP. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci 2009; 6(6):312-321. doi:10.7150/ijms.6.312. Available from http://www.medsci.org/v06p0312.htm